About the Program


On March 17, 2021, the U.S. Department of Health and Human Services (HHS) announced the Health Equity Initiative to increase access to COVID-19 monoclonal antibody (mAb) therapy for high-risk patients in underserved and disadvantaged communities across the country. The Department of Defense and HHS contracted with KPMG to develop prototype operational models for establishing or expanding capacity of mAb treatment, including building upon existing infrastructure and launching alternate treatment capabilities for eligible patients in high-risk communities across the United States.


Program participants in the Health Equity Initiative are encouraged to use Crush COVID to drive local marketing and outreach about mAb treatment. Through a variety of media channels, community and stakeholder outreach, and digital solutions, Crush COVID is helping program participants amplify their messaging about mAb treatment and ensure that patients in underserved and disadvantaged communities know where and how to get access to appropriate treatments for COVID-19.


The prototype model sites are designed to sustain, optimize, and expand treatment capabilities that allow patients to receive mAb therapy through a variety of approaches. The Initiative currently includes 30 prototype models, creating or expanding access to mAb treatment at roughly 90 locations in over 230 counties spanning 18 states across the country. Program participant press releases are available here.